Seattle Children's receives $5M gift from Ben Towne for pediatric cancer study

NewsGuard 100/100 Score

Seattle Children's Research Institute today announced a $5 million gift from Ben Towne Pediatric Cancer Research Foundation. The funding will be used to accelerate the work of Michael Jensen, MD, and his Seattle Children's Research Institute team who are creating new cancer treatments that reprogram a child's immune system to attack and kill cancer cells with the goal of minimizing or even eliminating the need for chemotherapy or radiation. To honor the Foundation, Seattle Children's Research Institute will give its Center for Childhood Cancer Research, led by Dr. Jensen, a new name: Ben Towne Center for Childhood Cancer Research.

Ben Towne was only three years old when he passed away in December 2008 from neuroblastoma, a rare pediatric cancer. His parents, Jeff and Carin, founders of Ben Towne Pediatric Cancer Research Foundation, said that in the aftermath of his death, they struggled with what to do as they moved forward with their lives. "We had seen so much suffering, not just in Ben's life but with other children and their families battling cancer," said Carin Towne.

"We felt like we were uniquely equipped to do something about it, so we started Ben Towne Pediatric Cancer Research Foundation with a mission to help find a cure for pediatric cancer. This next step for the Foundation honors Ben and his legacy, cements our partnership with Seattle Children's Research Institute and confirms our commitment to the work that will come out of Seattle on behalf of children everywhere," she said.

Dr. Jensen, director of the newly-named Ben Towne Center for Childhood Cancer Research, shares the Towne's vision. He joined Seattle Children's Research Institute in 2010 after spending 13 years at City of Hope, where he conducted the first FDA-authorized trial of T-cell therapies for children with recurrent neuroblastoma. Since joining Seattle Children's Research Institute, he has intensified his research efforts, focusing specifically on the most urgent needs of children battling cancer. He envisions the start of Phase I clinical trials with pediatric cancer patients by 2013.

"Ben Towne Pediatric Cancer Research Foundation is a tireless advocate for this work, leading a movement to change the way pediatric cancers are treated and someday cured," said Dr. Jensen. "Upon meeting Jeff and Carin, we immediately recognized our shared mission to cure pediatric cancer. Seattle Children's Research Institute is humbled by this gift, and is incredibly appreciative of the Foundation's support. Parents of children suffering from pediatric cancer ask the same question: 'Will that next breakthrough happen in time to save my child?' Thanks to this generous gift, we at Seattle Children's Research Institute can accelerate the process of creating treatments for cancer that are less traumatic for kids and that save lives."

While cancer treatments for adults encompass a multi-billion-dollar market that attracts investment from big pharmaceutical companies, childhood cancer does not receive this level of funding, despite the fact that cancer is the leading cause of childhood mortality by disease. "We want to cure children with cancer," said Dr. Jensen. "We have the knowledge, technologies and insights from decades of research. We're ready to make our vision a reality. We just need funding to complete the task, and the gift from Ben Towne Pediatric Cancer Research Foundation will be instrumental in helping us reach our goal even faster."

Source: Seattle Children's Research Institute

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Gut microbiome study challenges established cancer biomarkers, identifies new bacterial links to colorectal cancer